(Q79355854)

English

Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up

scientific article published on 14 November 2006

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17102802%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17102802%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

prostate cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Wirth M

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17102802%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Tyrrell C

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17102802%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Delaere K

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17102802%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Sánchez-Chapado M

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17102802%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Ramon J

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17102802%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Wallace DM

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17102802%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Hetherington J

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17102802%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Pina F

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17102802%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Heyns CF

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17102802%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Navani S

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17102802%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Armstrong J

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17102802%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

publication date

14 November 2006

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17102802%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Prostate Cancer and Prostatic Diseases

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17102802%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17102802%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17102802%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

87-93

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17102802%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Complications of advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500916

7 January 2021

based on heuristic

inferred from DOI database lookup

The psychological impact of cancer on patients' partners and other key relatives: a review

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500916

7 January 2021

based on heuristic

inferred from DOI database lookup

The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500916

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500916

7 January 2021

based on heuristic

inferred from DOI database lookup

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500916

7 January 2021

based on heuristic

inferred from DOI database lookup

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500916

7 January 2021

based on heuristic

inferred from DOI database lookup

BICALUTAMIDE MONOTHERAPY COMPARED WITH CASTRATION IN PATIENTS WITH NONMETASTATIC LOCALLY ADVANCED PROSTATE CANCER: 6.3 YEARS OF FOLLOWUP

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500916

7 January 2021

based on heuristic

inferred from DOI database lookup

Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500916

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500916

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of antiandrogen monotherapy in the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500916

7 January 2021

based on heuristic

inferred from DOI database lookup

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500916

7 January 2021

based on heuristic

inferred from DOI database lookup

Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500916

7 January 2021

based on heuristic

inferred from DOI database lookup

Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500916

7 January 2021

based on heuristic

inferred from DOI database lookup

Bicalutamide as Immediate Therapy Either Alone or as Adjuvant to Standard Care of Patients with Localized or Locally Advanced Prostate Cancer: First Analysis of the Early Prostate Cancer Program

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500916

7 January 2021

based on heuristic

inferred from DOI database lookup

Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500916

7 January 2021

based on heuristic

inferred from DOI database lookup

The bicalutamide Early Prostate Cancer Program. Demography

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500916

7 January 2021

based on heuristic

inferred from DOI database lookup

Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500916

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.PCAN.4500916

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17102802%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17102802%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q79355854&oldid=2223339772"